Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder.
1. Recent studies have provided support for the notion that the high affinity neurotrophin receptor tyrosine receptor kinase B (trk B) may be involved in the treatment of depression. 2. Using a quantitative RT-PCR approach trk B mRNA levels were determined in brain material from cerebellum, temporal cortex, and frontal cortex of control specimen and patients with major depressive disorder, schizophrenia and bipolar disorder (15 subjects each). 3. Interestingly, elevated trk B mRNA levels were found in cerebellum (3.6-fold) in patients with major depressive disorder, reaching statistical significance (p=0.03). 4. The major depressive disorder-on drugs group differed from controls (p=0.006) in the cerebellum. 5. Since only patients with major depressive disorder received antidepressants, elevated trk B mRNA levels are possibly related to drug treatment.
Bayer
T A
TA
Dept. of Psychiatry, University of Bonn Medical Center, Germany.
Schramm
M
M
Feldmann
N
N
Knable
M B
MB
Falkai
P
P
D000328:Adult; D000928:Antidepressive Agents / Q000494:pharmacology*; D001344:Autopsy; D001714:Bipolar Disorder / Q000188:drug therapy / Q000503:physiopathology; D002531:Cerebellum / Q000737:chemistry; D003866:Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005625:Frontal Lobe / Q000737:chemistry; D006801:Humans; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000032:analysis; D020794:Receptor Protein-Tyrosine Kinases / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology; D013702:Temporal Lobe / Q000737:chemistry*
D000928:Antidepressive Agents; D012333:RNA, Messenger; D020794:Receptor Protein-Tyrosine Kinases